Korean J Urol.  2015 Oct;56(10):673-679. 10.4111/kju.2015.56.10.673.

Drug therapy of overactive bladder - What is coming next?

• Andersson

• KMID: 2344109
• DOI: http://doi.org/10.4111/kju.2015.56.10.673

Abstract

After the approval and introduction of mirabegron, tadalafil, and botulinum toxin A for treatment of lower urinary tract symptoms/overactive bladder, focus of interest has been on their place in therapy versus the previous gold standard, antimuscarinics. However, since these agents also have limitations there has been increasing interest in what is coming next - what is in the pipeline? Despite progress in our knowledge of different factors involved in both peripheral and central modulation of lower urinary tract dysfunction, there are few innovations in the pipe-line. Most developments concern modifications of existing principles (antimuscarinics, beta3-receptor agonists, botulinum toxin A). However, there are several new and old targets/drugs of potential interest for further development, such as the purinergic and cannabinoid systems and the different members of the transient receptor potential channel family. However, even if there seems to be good rationale for further development of these principles, further exploration of their involvement in lower urinary tract function/dysfunction is necessary.

Keyword

Cannabinoids; Purinergic receptors; Transient receptor potential channels

MeSH Terms

Adrenergic beta-3 Receptor Agonists/therapeutic use
Botulinum Toxins, Type A/therapeutic use
Drug Therapy, Combination
Humans
Molecular Targeted Therapy/methods/trends
Muscarinic Antagonists/therapeutic use
Neuromuscular Agents/therapeutic use
Urinary Bladder, Overactive/*drug therapy
Adrenergic beta-3 Receptor Agonists
Muscarinic Antagonists
Neuromuscular Agents
Botulinum Toxins, Type A

Reference

1. Andersson KE, Martin N, Nitti V. Selective β3-adrenoceptor agonists for the treatment of overactive bladder. J Urol. 2013; 190:1173–1180.

2. Chapple CR, Cardozo L, Nitti VW, Siddiqui E, Michel MC. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn. 2014; 33:17–30.

3. Mangera A, Apostolidis A, Andersson KE, Dasgupta P, Giannantoni A, Roehrborn C, et al. An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders. Eur Urol. 2014; 65:981–990.

4. Lythgoe C, McVary KT. The use of PDE-5 inhibitors in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Curr Urol Rep. 2013; 14:585–594.

5. Yeo EK, Hashim H, Abrams P. New therapies in the treatment of overactive bladder. Expert Opin Emerg Drugs. 2013; 18:319–337.

6. Zacche MM, Giarenis I, Cardozo L. Phase II drugs that target cholinergic receptors for the treatment of overactive bladder. Expert Opin Investig Drugs. 2014; 23:1365–1374.

7. Sacco E, Bientinesi R. Innovative pharmacotherapies for women with overactive bladder: where are we now and what is in the pipeline? Int Urogynecol J. 2015; 26:629–640.

8. Bechis SK, Kim MM, Wintner A, Kreydin EI. Differential response to medical therapy for male lower urinary tract symptoms. Curr Bladder Dysfunct Rep. 2015; 10:177–185.

9. Salcedo C, Davalillo S, Cabellos J, Lagunas C, Balsa D, Perez-Del-Pulgar S, et al. In vivo and in vitro pharmacological characterization of SVT-40776, a novel M3 muscarinic receptor antagonist, for the treatment of overactive bladder. Br J Pharmacol. 2009; 156:807–817.

10. Song M, Kim JH, Lee KS, Lee JZ, Oh SJ, Seo JT, et al. The efficacy and tolerability of tarafenacin, a new muscarinic acetylcholine receptor M3 antagonist in patients with overactive bladder; randomised, double-blind, placebo-controlled phase 2 study. Int J Clin Pract. 2015; 69:242–250.

11. Michel MC, Igawa Y. Therapeutic targets for overactive bladder other than smooth muscle. Expert Opin Ther Targets. 2015; 19:687–705.

12. Dmochowski RR, Staskin DR, Duchin K, Paborji M, Tremblay TM. Clinical safety, tolerability and efficacy of combination tolterodine/pilocarpine in patients with overactive bladder. Int J Clin Pract. 2014; 68:986–994.

13. Andersson KE, Campeau L, Olshansky B. Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction. Br J Clin Pharmacol. 2011; 72:186–196.

14. Rosa GM, Bauckneht M, Scala C, Tafi E, Leone Roberti Maggiore U, Ferrero S, et al. Cardiovascular effects of antimuscarinic agents in overactive bladder. Expert Opin Drug Saf. 2013; 12:815–827.

15. Biers SM, Reynard JM, Brading AF. The effects of a new selective beta3-adrenoceptor agonist (GW427353) on spontaneous activity and detrusor relaxation in human bladder. BJU Int. 2006; 98:1310–1314.

16. Takasu T, Ukai M, Sato S, Matsui T, Nagase I, Maruyama T, et al. Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther. 2007; 321:642–647.

17. Hatanaka T, Ukai M, Watanabe M, Someya A, Ohtake A, Suzuki M, et al. In vitro and in vivo pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in rats. J Naunyn Schmiedebergs Arch Pharmacol. 2013; 386:247–253.

18. Igawa Y, Michel MC. Pharmacological profile of β3-adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome. Naunyn Schmiedebergs Arch Pharmacol. 2013; 386:177–183.

19. Gillespie JI, Palea S, Guilloteau V, Guerard M, Lluel P, Korstanje C. Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction. BJU Int. 2012; 110(2 Pt 2):E132–E142.

20. Aizawa N, Homma Y, Igawa Y. Effects of mirabegron, a novel β3-adrenoceptor agonist, on primary bladder afferent activity and bladder microcontractions in rats compared with the effects of oxybutynin. Eur Urol. 2012; 62:1165–1173.

21. Eastham JE, Gillespie JI. The concept of peripheral modulation of bladder sensation. Organogenesis. 2013; 9:224–233.

22. Gillespie JI, Rouget C, Palea S, Granato C, Korstanje C. Beta adrenergic modulation of spontaneous microcontractions and electrical field-stimulated contractions in isolated strips of rat urinary bladder from normal animals and animals with partial bladder outflow obstruction. Naunyn Schmiedebergs Arch Pharmacol. 2015; 388:719–726.

23. Gillespie JI, Rouget C, Palea S, Granato C, Birder L, Korstanje C. The characteristics of intrinsic complex micro-contractile activity in isolated strips of the rat bladder. Naunyn Schmiedebergs Arch Pharmacol. 2015; 388:709–718.

24. Granato C, Korstanje C, Guilloteau V, Rouget C, Palea S, Gillespie JI. Prostaglandin E2 excitatory effects on rat urinary bladder: a comparison between the β-adrenoceptor modulation of non-voiding activity in vivo and micro-contractile activity in vitro. Naunyn Schmiedebergs Arch Pharmacol. 2015; 388:727–735.

25. Rouget C, Rekik M, Camparo P, Botto H, Rischmann P, Lluel P, et al. Modulation of nerve-evoked contractions by β3-adrenoceptor agonism in human and rat isolated urinary bladder. Pharmacol Res. 2014; 80:14–20.

26. D'Agostino G, Maria Condino A, Calvi P. Involvement of β3-adrenoceptors in the inhibitory control of cholinergic activity in human bladder: Direct evidence by [(3)H]-acetylcholine release experiments in the isolated detrusor. Eur J Pharmacol. 2015; 758:115–122.

27. Ohlstein EH, von Keitz A, Michel MC. A multicenter, double-blind, randomized, placebo-controlled trial of the β3-adrenoceptor agonist solabegron for overactive bladder. Eur Urol. 2012; 62:834–840.

28. Leon LA, Hoffman BE, Gardner SD, Laping NJ, Evans C, Lashinger ES, et al. Effects of the beta 3-adrenergic receptor agonist disodium 5-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl] amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL-316243) on bladder micturition reflex in spontaneously hypertensive rats. J Pharmacol Exp Ther. 2008; 326:178–185.

29. Tasler S, Baumgartner R, Behr-Roussel D, Oger-Roussel S, Gorny D, Giuliano F, et al. An aryloxypropanolamine hβ3-adrenoceptor agonist as bladder smooth muscle relaxant. Eur J Pharm Sci. 2012; 46:381–387.

30. Moyes CR, Berger R, Goble SD, Harper B, Shen DM, Wang L, et al. Design, synthesis, and evaluation of conformationally restricted acetanilides as potent and selective β3 adrenergic receptor agonists for the treatment of overactive bladder. J Med Chem. 2014; 57:1437–1453.

31. Kanie S, Otsuka A, Yoshikawa S, Kobayashi R, Itaba S, Yokokawa H, et al. TRK-380, a novel selective human β3-adrenoceptor agonist, ameliorates formalin-induced pollakiuria in rats and carbachol-induced bladder contraction in dogs. Urology. 2013; 82:975.e7–975.e12.

32. Otsuka A, Shinbo H, Hasebe K, Matsumoto R, Ozono S. Effects of a novel beta(3)-adrenoceptor agonist, AJ-9677, on relaxation of the detrusor muscle: an in vitro study. Int J Urol. 2008; 15:1072–1076.

33. Afeli SA, Rovner ES, Petkov GV. BRL37344, a β3-adrenergic receptor agonist, decreases nerve-evoked contractions in human detrusor smooth muscle isolated strips: role of BK channels. Urology. 2013; 82:744.e1–744.e7.

34. Keith F, John C. Targeted secretion inhibitors-innovative protein therapeutics. Toxins (Basel). 2010; 2:2795–2815.

35. Edupuganti OP, Ovsepian SV, Wang J, Zurawski TH, Schmidt JJ, Smith L, et al. Targeted delivery into motor nerve terminals of inhibitors for SNARE-cleaving proteases via liposomes coupled to an atoxic botulinum neurotoxin. FEBS J. 2012; 279:2555–2567.

36. Kuo HC, Liu HT, Chuang YC, Birder LA, Chancellor MB. Pilot study of liposome-encapsulated onabotulinumtoxina for patients with overactive bladder: a single-center study. Eur Urol. 2014; 65:1117–1124.

37. Kane CD, Nuss JE, Bavari S. Novel therapeutic uses and formulations of botulinum neurotoxins: a patent review (2012 - 2014). Expert Opin Ther Pat. 2015; 25:675–690.

38. Chuang YC, Tyagi P, Huang CC, Yoshimura N, Wu M, Kaufman J, et al. Urodynamic and immunohistochemical evaluation of intravesical botulinum toxin A delivery using liposomes. J Urol. 2009; 182:786–792.

39. ClinicalTrials.gov [Internet]. Bethesda (MD): National Institutes of Health;c2015. [cited 2015 Jul 28]. Available from: https://clinicaltrials.gov/.

40. Füllhase C, Chapple C, Cornu JN, De Nunzio C, Gratzke C, Kaplan SA, et al. Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms. Eur Urol. 2013; 64:228–243.

41. Lee SH, Lee JY. Current role of treatment in men with lower urinary tract symptoms combined with overactive bladder. Prostate Int. 2014; 2:43–49.

42. Schauer I, Madersbacher S. Medical treatment of lower urinary tract symptoms/benign prostatic hyperplasia: anything new in 2015. Curr Opin Urol. 2015; 25:6–11.

43. Abrams P, Kelleher C, Staskin D, Rechberger T, Kay R, Martina R, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). Eur Urol. 2015; 67:577–588.

44. Bechis SK, Otsetov AG, Ge R, Olumi AF. Personalized medicine for the management of benign prostatic hyperplasia. J Urol. 2014; 192:16–23.

45. Ochodnicky P, Cruz CD, Yoshimura N, Cruz F. Neurotrophins as regulators of urinary bladder function. Nat Rev Urol. 2012; 9:628–637.

46. Cruz CD. Neurotrophins in bladder function: what do we know and where do we go from here? Neurourol Urodyn. 2014; 33:39–45.

47. Seth JH, Sahai A, Khan MS, van der Aa F, de Ridder D, Panicker JN, et al. Nerve growth factor (NGF): a potential urinary biomarker for overactive bladder syndrome (OAB)? BJU Int. 2013; 111:372–380.

48. Evans RJ, Moldwin RM, Cossons N, Darekar A, Mills IW, Scholfield D. Proof of concept trial of tanezumab for the treatment of symptoms associated with interstitial cystitis. J Urol. 2011; 185:1716–1721.

49. Leite VF, Buehler AM, El Abd O, Benyamin RM, Pimentel DC, Chen J, et al. Anti-nerve growth factor in the treatment of low back pain and radiculopathy: a systematic review and a metaanalysis. Pain Physician. 2014; 17:E45–E60.

50. Sopata M, Katz N, Carey W, Smith MD, Keller D, Verburg KM, et al. Efficacy and safety of tanezumab in the treatment of pain from bone metastases. Pain. 2015; 156:1703–1713.

51. Rahnama'i MS, van Kerrebroeck PE, de Wachter SG, van Koeveringe GA. The role of prostanoids in urinary bladder physiology. Nat Rev Urol. 2012; 9:283–290.

52. Chapple CR, Abrams P, Andersson KE, Radziszewski P, Masuda T, Small M, et al. Phase II study on the efficacy and safety of the EP1 receptor antagonist ONO-8539 for nonneurogenic overactive bladder syndrome. J Urol. 2014; 191:253–260.

53. Christ GJ, Andersson KE. Rho-kinase and effects of Rho-kinase inhibition on the lower urinary tract. Neurourol Urodyn. 2007; 26:6 Suppl. 948–954.

54. Morelli A, Vignozzi L, Filippi S, Vannelli GB, Ambrosini S, Mancina R, et al. BXL-628, a vitamin D receptor agonist effective in benign prostatic hyperplasia treatment, prevents RhoA activation and inhibits RhoA/Rho kinase signaling in rat and human bladder. Prostate. 2007; 67:234–247.

55. Penna G, Fibbi B, Amuchastegui S, Corsiero E, Laverny G, Silvestrini E, et al. The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways. Prostate. 2009; 69:480–493.

56. Digesu GA, Verdi E, Cardozo L, Olivieri L, Khullar V, Colli E. Phase IIb, multicenter, double-blind, randomized, placebocontrolled, parallel-group study to determine effects of elocalcitol in women with overactive bladder and idiopathic detrusor overactivity. Urology. 2012; 80:48–54.

57. Petkov GV. Role of potassium ion channels in detrusor smooth muscle function and dysfunction. Nat Rev Urol. 2011; 9:30–40.

58. Andersson KE, Chapple CR, Cardozo L, Cruz F, Hashim H, Michel MC, et al. Pharmacological treatment of urinary incontinence.In : Abrams P, Cardozo L, Khoury S, Wein AJ, editors. Incontinence, 5th International Consultation on Incontinence. [Paris]: ICUD-EAU;2013. p. 623–728.

59. Christ GJ, Day NS, Day M, Santizo C, Zhao W, Sclafani T, et al. Bladder injection of "naked" hSlo/pcDNA3 ameliorates detrusor hyperactivity in obstructed rats in vivo. Am J Physiol Regul Integr Comp Physiol. 2001; 281:R1699–R1709.

60. Andersson KE. LUTS treatment: future treatment options. Neurourol Urodyn. 2007; 26:6 Suppl. 934–947.

61. Ford AP, Cockayne DA. ATP and P2X purinoceptors in urinary tract disorders. Handb Exp Pharmacol. 2011; (202):485–526.

62. Ford AP, Undem BJ. The therapeutic promise of ATP antagonism at P2X3 receptors in respiratory and urological disorders. Front Cell Neurosci. 2013; 7:267.

63. North RA, Jarvis MF. P2X receptors as drug targets. Mol Pharmacol. 2013; 83:759–769.

64. Andersson KE. Purinergic signalling in the urinary bladder. Auton Neurosci. 2015; 191:78–81.

65. Tyagi P, Tyagi V, Yoshimura N, Chancellor M. Functional role of cannabinoid receptors in urinary bladder. Indian J Urol. 2010; 26:26–35.

66. Ruggieri MR Sr. Cannabinoids: potential targets for bladder dysfunction. Handb Exp Pharmacol. 2011; (202):425–451.

67. Hedlund P. Cannabinoids and the endocannabinoid system in lower urinary tract function and dysfunction. Neurourol Urodyn. 2014; 33:46–53.

68. Everaerts W, Gevaert T, Nilius B, De Ridder D. On the origin of bladder sensing: Tr(i)ps in urology. Neurourol Urodyn. 2008; 27:264–273.

69. Andersson KE, Gratzke C, Hedlund P. The role of the transient receptor potential (TRP) superfamily of cation-selective channels in the management of the overactive bladder. BJU Int. 2010; 106:1114–1127.

70. Skryma R, Prevarskaya N, Gkika D, Shuba Y. From urgency to frequency: facts and controversies of TRPs in the lower urinary tract. Nat Rev Urol. 2011; 8:617–630.

71. Avelino A, Charrua A, Frias B, Cruz C, Boudes M, de Ridder D, et al. Transient receptor potential channels in bladder function. Acta Physiol (Oxf). 2013; 207:110–122.

72. Deruyver Y, Voets T, De Ridder D, Everaerts W. Transient receptor potential channel modulators as pharmacological treatments for lower urinary tract symptoms (LUTS): myth or reality? BJU Int. 2015; 115:686–697.

73. Franken J, Uvin P, De Ridder D, Voets T. TRP channels in lower urinary tract dysfunction. Br J Pharmacol. 2014; 171:2537–2551.

74. Fullhase C, Russo A, Castiglione F, Benigni F, Campeau L, Montorsi F, et al. Spinal cord FAAH in normal micturition control and bladder overactivity in awake rats. J Urol. 2013; 189:2364–2370.